Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics

DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sarcopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcopenia Market Forecast
https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Sarcopenia Market Report:
• The Sarcopenia market size was valued ~USD 2,200 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for autoimmune and inflammatory diseases, announced that findings from its Phase 2a clinical trial of isomyosamine, an oral TNF-alpha (TNF-α) inhibitor, were presented last week during a podium session at the 15th International Conference on Frailty and Sarcopenia Research (ICFSR).
• In March 2025, Immunis, Inc., a clinical-stage biotechnology company focused on developing multi-active biologics for immune dysregulation linked to aging and disease, has begun treating multiple patients in its STEM-META Phase 2 clinical trial. This trial aims to evaluate the safety and tolerability of IMM01-STEM, an investigational therapy, in older adults with sarcopenia (muscle atrophy) associated with obesity. The study builds on findings from the company's previous Phase 1/2a trial, which investigated IMM01-STEM in adults with sarcopenia related to knee osteoarthritis.
• In January 2025, Epirium Bio, Inc. (Epirium), a biopharmaceutical company focused on developing treatments for neuromuscular and fibrotic diseases, has begun dosing healthy volunteers in its Phase 1 dose-escalation clinical trial of MF-300. This investigational, first-in-class oral therapy is a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor being developed to treat sarcopenia, a condition characterized by age-related muscle weakness.
• In 2024, the total number of diagnosed prevalent cases of sarcopenia across the 7MM was approximately 19,836,200, with projections indicating a rise throughout the study period (2020-2034).
• In 2024, the UK had the highest number of diagnosed prevalent cases of sarcopenia among the EU4 and the UK, followed by Germany, while Spain reported the lowest number of cases.
• In the US, sarcopenia cases are categorized by age groups: 65-69 years, 70-79 years, and 80 years and older. In 2024, the 65-69 age group had the highest number of cases, estimated at approximately 4,520,200.
• In Japan, the estimated number of sarcopenia cases was around 5,225,100 in 2024.
• Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others
• Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others
• The Sarcopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sarcopenia pipeline products will significantly revolutionize the Sarcopenia market dynamics.

Sarcopenia Overview
Sarcopenia is a condition characterized by the gradual loss of muscle mass, strength, and function, typically associated with aging. It can lead to physical frailty, reduced mobility, and an increased risk of falls and fractures. Sarcopenia is often diagnosed through a combination of muscle mass measurements and assessments of strength or physical performance. It can be influenced by factors such as inactivity, poor nutrition, chronic illness, and hormonal changes. Early detection and management through exercise, diet, and, in some cases, medication, can help mitigate its effects.

Get a Free sample for the Sarcopenia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sarcopenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sarcopenia Epidemiology Segmentation:
The Sarcopenia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Sarcopenia
• Prevalent Cases of Sarcopenia by severity
• Gender-specific Prevalence of Sarcopenia
• Diagnosed Cases of Episodic and Chronic Sarcopenia

Download the report to understand which factors are driving Sarcopenia epidemiology trends @ Sarcopenia Epidemiology Forecast
https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sarcopenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcopenia market or expected to get launched during the study period. The analysis covers Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sarcopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sarcopenia Therapies and Key Companies
• MYMD-1/Isomyosamine: TNF Pharmaceuticals
• LPCN 1148: Lipocine
• Sarconeos (BIO101): Biophytis
• Froniglutide (PF-1801): ImmunoForge
• RJx-01: Rejuvenate Biomed
• KER-065: Keros Therapeutics
• BPM 31510 (ubidecarenone): BPGbio
• OC514: Oncocross
• MT29: Mirscience Therapeutics
• TRN-005: Turn Biotechnologies
• NMDP-05: NMD PHARMA
• PF1807: ImmunoForge
• DW1030: Dong Wha PHARM

Discover more about therapies set to grab major Sarcopenia market share @ Sarcopenia Treatment Landscape
https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sarcopenia Market Strengths
• Lifestyle modifications, including exercise and proper nutrition, have shown efficacy in preventing and managing sarcopenia.

Sarcopenia Market Opportunities
• Improved integration of sarcopenia screening and management into routine healthcare practices can enhance early detection and intervention.

Scope of the Sarcopenia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others
• Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others
• Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies
• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Sarcopenia Unmet Needs, KOL's views, Analyst's views, Sarcopenia Market Access and Reimbursement

To know more about Sarcopenia companies working in the treatment market, visit @ Sarcopenia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Sarcopenia Market Report Introduction
2. Executive Summary for Sarcopenia
3. SWOT analysis of Sarcopenia
4. Sarcopenia Patient Share (%) Overview at a Glance
5. Sarcopenia Market Overview at a Glance
6. Sarcopenia Disease Background and Overview
7. Sarcopenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Sarcopenia
9. Sarcopenia Current Treatment and Medical Practices
10. Sarcopenia Unmet Needs
11. Sarcopenia Emerging Therapies
12. Sarcopenia Market Outlook
13. Country-Wise Sarcopenia Market Analysis (2020-2034)
14. Sarcopenia Market Access and Reimbursement of Therapies
15. Sarcopenia Market Drivers
16. Sarcopenia Market Barriers
17. Sarcopenia Appendix
18. Sarcopenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Sarcopenia Pipeline https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Sarcopenia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sarcopenia market. A detailed picture of the Sarcopenia pipeline landscape is provided, which includes the disease overview and Sarcopenia treatment guidelines.

Sarcopenia Epidemiology https://www.delveinsight.com/report-store/sarcopenia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Sarcopenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Sarcopenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.